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Background: The mechanism of IL-1 release 
from endothelial cells is not fully known. 
Results: Neutrophil elastase causes secretion of 
bioactive IL-1 from endothelial cells via 
microvesicles. 
Conclusion: A mechanistic link between IL-1 
secretion from endothelial cells and neutrophil 
elastase in atherosclerotic plaques is revealed. 
Significance: Neutrophil elastase could be a 
potential target for preventing atherosclerosis. 
 
ABSTRACT 
The endothelium is critically involved in 
the pathogenesis of atherosclerosis by 
producing proinflammatory mediators, 
including interleukin-1 beta (IL-1β). Coronary 
arteries from patients with ischaemic heart 
disease express large amounts of IL-1β in 
endothelium. However, the mechanism by 
which endothelial cells (ECs) release IL-1β 
remains to be elucidated. We investigated 
neutrophil elastase (NE), a potent serine 
protease detected in vulnerable areas of human 
carotid plaques, as a potential ‘trigger’ for IL-
1β processing and release. This study tested the 
hypothesis that NE potentiates the processing 
and release of IL-1β from human coronary 
endothelium. We found that NE cleaves the 
pro-isoform of IL-1β in ECs and causes 
significant secretion of bioactive IL-1β via 
extracellular vesicles. This release was 
significantly attenuated by inhibition of 
neutrophil elastase, but not caspase-1. 
Transient increases in intracellular Ca2+ levels 
were observed prior to secretion. Inside ECs, 
and after NE treatment only, IL-1β was 
detected within LAMP-1 positive multivesicular 
bodies (MVBs).  The released vesicles contained 
bioactive IL-1β. In vivo, in experimental 
atherosclerosis, NE was detected in mature 
atherosclerotic plaques, predominantly in the 
endothelium, alongside IL-1β. This study 
reveals a novel mechanistic link between NE 
expression in atherosclerotic plaques and 
concomitant pro-inflammatory bioactive IL-1β 
secretion from ECs; this could reveal additional 
potential anti-IL-1β therapeutic targets and 
provide further insight into the inflammatory 
process by which vascular disease develops.  
 
Atherosclerosis is a complex chronic 
inflammatory disease that involves inflammatory 
cell recruitment and release of pro-inflammatory 
cytokines (1). Interleukin (IL)-1β has been 
implicated in several aspects of vascular 
inflammation and neointima formation (2).  
Endothelial cell dysfunction, promoted by IL-1, 
also plays a central role in atherogenesis, by 
expression of adhesion molecules and cytokine 
secretion (3), facilitating leukocyte recruitment 
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and plaque development. The culmination of two 
decades of pre clinical experimental studies in the 
IL-1 field has led to the ongoing phase 3 clinical 
trial Cankinumab Anti-inflammatory Thrombosis 
Outcomes Study (CANTOS) which will test 
whether blocking IL-1β only will reduce incidence 
of thrombotic events in patients after myocardial 
infarction that remain at high risk due to ongoing 
inflammation (4). 
It has generally been assumed that IL-1β is 
produced predominantly by immune derived cells 
(5). However, we showed in ischemic heart 
disease (IHD) patients that atherosclerotic 
coronary arteries synthesise and express 
significant IL-1β within the endothelium (6) 
compared to controls.  Experimental studies have 
also indicated that cultured endothelial cells (ECs) 
synthesize IL-1β in response to different cytokine 
stimulations, but that the released IL-1β is low and 
relatively inefficient (7). It is crucial therefore to 
understand the mechanism(s) of release of IL-1β 
from ECs especially since IL-1β acts at a distance 
rather than just locally in the vessel wall. 
IL-1β production is a two-step controlled 
process, requiring an ‘initial’ stimulus for 
transcription/translation of proIL-1β (31kDa) 
which, in turn, is cleaved by an inflammasome-
activated caspase-1 (8) (‘a second hit’) into a 
biologically active isoform (17KDa), before 
secretion. The cleavage of proIL-1β is a crucial 
step and studies in monocytes show that caspase-1 
(a cysteine protease) is a cardinal enzyme in this 
process(9). There is a spectrum of proposed 
cellular mechanisms responsible for IL-1 secretion 
in monocytic cells – including rescue from 
autophagy and subsequent release, release via 
microvesicles or multivesicular bodies and 
terminal release (via pores), dependent on cell type 
and stimulus intensity (10). 
In vivo studies have postulated that IL-1β 
can also be released in the absence of caspase-
1(11) suggesting an alternative, and yet unknown, 
mechanism by which ‘leaderless’ IL-1β is 
secreted. There are other potential enzymes that 
cleave proIL-1β into its mature form, including the 
serine proteases (neutrophil elastase, cathepsin G 
and proteinase 3, (12,13)). It is known that in cell-
free systems, these serine proteases cleave purified 
proIL-1β into a biologically active IL-1β in vitro at 
distinct sites to caspase-1 with production of 
18kDa and 20kDa isoforms of IL-1β. However, 
whether, and to what extent, these proteases could 
contribute to IL-1β release in cells such as ECs is 
relatively unknown. 
Neutrophil elastase (NE) is a potent serine 
protease that has wide substrate specificity (14) 
(15). Experimental studies have potentially 
focused on the destructive nature of NE, but 
interesting recent data show that NE can provoke a 
variety of pro-inflammatory responses such as IL-
8 release from bronchial epithelium and TGF-β 
production in bronchial smooth muscle cells (14). 
Moreover, deletion of NE in mice leads to 
reduction of serum inflammatory biomarkers such 
as TNF-α, MCP-1, and IL-1 (16). One study has 
also demonstrated NE in macrophage rich human 
atherosclerotic plaque shoulders (17) and it also 
appears critical in caspase-1 independent IL-1β 
generation in NE-induced lung (18) and renal 
injury (19). In this study, we sought to determine 
whether NE promotes biologically active IL-1β 
secretion from vascular endothelium. We show 
that NE stimulation leads to pro-IL-1β cleavage 
and increases IL-1β release from coronary artery 
ECs via a caspase-1 independent, vesicular-release 
mediated process. Furthermore, we demonstrate 
that IL-1β is colocalized with NE predominantly in 
the endothelium in experimental atherosclerosis. 
This very first demonstration and explanation of 
active IL-1β release from endothelium potentially 
provides novel additional strategies for inhibition 
of IL-1β activity in inflammatory cardiovascular 
disease. 
 
EXPERIMENTAL PROCEDURES 
Human coronary artery endothelial cells 
(HCAECs) were purchased from PromoCell 
(Heidelberg, Germany) and cultured in 
supplemented media according to the 
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manufacturer’s recommendations. The cells, at 
passage 2-5, were seeded into 6 well plates (2x104 
cells/well) and grown at 37ºC/ 5% CO2 (v/v) until 
70% confluent. The first step of stimulation was to 
up-regulate proIL-1β production by adding 
cytokines (TNF-α/IL-1α; 10ng/ml each) for 48h as 
previously described (7). Cells were then washed 
to remove all traces of stimulating cytokines 
before the media was replaced with serum free 
media containing NE (1µg/ml; equating to 60IU). 
To ensure the stimulating cytokines were 
completely removed, the final cell wash was tested 
for presence of IL-1 via ELISA. No cytokines 
were detected in these washes (data not shown). In 
some experiments, cells were pre-incubated with 
NEIII (500µM) (20), caspase-1 inhibitor I 
(YVAD; 50µM) (21) (8); or BAF1 (50nM) (22) 
for at least 30 minutes before the addition of NE. 
At the end of incubations, supernatants were 
collected and the cells were lysed in ice-cold 1% 
(v/v) Triton-X100 lysis buffer. Both supernatant 
and cell lysates were stored at -80ºC until analysis 
was conducted.  
Determination of cell viability: Cell 
viability was evaluated by Trypan blue dye 
exclusion and by measurement of lactate 
dehydrogenase (LDH) levels in conditioned media. 
LDH detected in cell lysates was used as a positive 
control for total LDH. Levels of LDH were 
analysed using CytoTox 96 Non-Radioactive 
cytotoxicity kit (Promega, USA) according to the 
manufacturer’s instructions. 
NE activity: NE activity was measured 
spectrophotometrically using a highly specific 
synthetic substrate (Elastase Substrate I, MeOSuc-
Ala-Pro-Val-pNA; 100µM) as described in detail 
(14), (23). Briefly, samples (supernatant and 
lysate) were added to assay buffer (0.45 Tris-Base 
and 2M NaCl; pH. 8.0) containing Elastase 
Substrate I for 6h. The rate of the substrate 
cleavage was measured using a plate reader 
(Thermo Scientific) at 410nm.  
ELISA for IL-1β: The concentrations of 
IL-1β (pg/ml) in the supernatants and lysates were 
quantified by ELISA Quantikine kits (R&D 
systems) according to manufacturer’s 
recommendations.  
Apoptosis: Apoptosis, detected via 
caspase-3/7 activity, was analysed by Caspase-
Glo® 3/7 assay (Promega) according to 
manufacturer’s recommendations. 
Western blot analysis for IL-1β processing 
and release: Samples (lysates and concentrated 
supernatants using 10k Amicon filter devices 
(ThermoScientific)) were subjected to Western 
blotting.  
Microvesicle isolation: MV isolation was 
conducted as described (24). Freshly prepared 
MVs were used for analysis, to avoid false-
positive effects caused by leakage of contents from 
MVs damaged by freeze-thawing. 
Flow cytometry measurement of 
extracellular vesicles (ECV): A pellet of ECV was 
resuspended in annexinV-binding buffer and 
labelled with annexin V PE-Cy7 fluorescence 
according to the manufacturer’s instructions 
(eBioscience, UK). Events were acquired using 
LSR II flow cytometer (BD Biosciences) and 
annexin-V positive ECV were enumerated using 
Accu Count Beads (SPHERO, 0.2-0.9µm) and 
analysed using FlowJo software (TreeStar). 
Measurements of Intracellular Calcium 
concentration: HCAECs in 96 well plates at a 
seeding density of 5x103 were treated with 
cytokines or left untreated for 48h. Fura-4 was 
then added to the cells according to manufacturer’s 
instructions (Invitrogen). After washing off the 
dye, the cells were incubated with or without NE 
and changes in cytosolic Ca2+ were recorded using 
a plate reader (Thermo Scientific) according to 
manufacturer’s recommendations.  EGTA (6mM) 
and Ionophore A3784 (10µM) were used as 
controls as previously described (25).  
Direct effects of NE on rIL-1β /ProIL-1β: 
NE is known to undergo spontaneous autolysis 
(26) and has a proteolytic activity against many 
cytokines such as TNF-α (15). For this reason, we 
tested the effect of NE with the studied 
concentration on IL-1β/proIL-1β itself. IL-1β 
standard (R&D) at a concentration of 125pg/ml 
and proIL-1β standard (R&D) at a concentration of 
10000pg/ml were separately mixed with NE 
(1µg/ml) and kept in the incubator for 30 min, 2h 
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and 6h. The samples were stored at -800C and 
tested by ELISA and western blot.  
Detection of extracellular vesicular 
shedding:  HCAECs (2x104) were plated in 
LabTek (Fisher) 8-well chamber slides and 
subjected to the above-mentioned stimulation 
conditions. AnnexinV-Alexa Fluor® 488 
(Invitrogen) was then added to the cells at 
5µl/well. MV shedding was visualised using image 
acquisition software (Inverted widefield 
fluorescence microscope Leica AF6000 Time 
Lapse) after the addition of NE in a 5% CO2/ 37oC 
(v/v) heated chamber. The images were captured 
after 15, 30min, 2h and 6h and analysed using 
Image J software (NIH). MVs (0.1-1µm) were 
quantified in blinded samples in a random field of 
cells.   
Immunofluorescence: Cells were fixed 
with 4% w/v paraformaldehyde and permeabilized 
in 0.3% v/v Triton-X 100. Non-specific binding 
was blocked for 30min with 5% v/v goat or rabbit 
serum in 1% w/v BSA prior to sequential 
incubation of the cells with primary antibodies: 
anti-goat IL-1β and anti-rabbit LAMP-1 (1:100 
dilutions). Alexa fluor 647 and 488 conjugated 
secondary antibodies were used in 1% w/v BSA 
(1:200 dilution). The coverslips were washed with 
PBS and mounted onto glass slides using media 
containing DAPI.   
The labelling of NE was conducted as previously 
described (27) using a Microscale Protein 
Labelling kit (Molecular Probes) according to 
manufacturer’s instructions. 50µg NE was used for 
the reaction. Final concentration of Alexa647-NE 
was 0.1 mg/ml in a volume of 100µl.  
Determination of IL-1β biological activity: 
The bioactivity of the secreted IL-1β by HCAECs 
following NE stimulation was assessed using an 
IL-8 luciferase reporter assay, sensitive to 
picomolar concentrations of IL-1β, as previously 
described  (9); (28); (29). Briefly, HeLa cells 
(5x103) were grown to 70% confluence in 96 well 
plates and transfected with a total of 100ng 
DNA/well; including 60ng pIL-8-luc (reporter) 
and 40ng pRL-TK (internal control). After 24h, 
transfection efficiency was assessed and cells were 
then stimulated for 6h with 0.1nM of IL-1β as a 
control or with harvested supernatants from 
HCAEC stimulated with NE. IL-1 beta 
neutralising antibody (1ug/ml, MAB201, R&D 
Systems) was used in some wells, to prove 
specificity. Cells were then lysed with passive 
lysis buffer (Promega) and transferred to white 
well plates to assay for luminescence intensity 
using LARII and Stop and Glo reagents 
(Promega). Luciferase activity was calculated by 
normalising to the Renilla luminescence measured 
in each well according to manufacturer’s 
recommendations (Promega).  
Conventional and Immunogold Labelling 
Electron Microscopy: EC pellets (NE or untreated 
controls) were processed as previously described 
(30). Thin sections were immunogold labelled 
with primary antibodies: anti-goat IL-1β and anti-
rabbit LAMP-1 (1:50 dilutions each) for 2h at 
room temperature. After washing the grids, the 
sections were incubated with immunogold 
conjugated secondary antibodies (20nm& 10nm 
gold particles, Agar Scientific, UK) for 2h. 
Control experiments were performed by using 
PBS instead of the primary antibodies and all 
sections were then post-stained with uranyl acetate 
and lead citrate.  
Mice and diets: ApoE-/- male mice were 
bred in-house at the University of Sheffield. Food 
and water were given ad libitum under a controlled 
environment (Temp. 22-25ᵒC, humidity 55±5 and 
12h light cycle). At 8-10 weeks of age, the mice 
were housed individually and fed a high fat, 
Western-type diet (HFD) containing 21% fat, 
0.15% cholesterol and 0.296% sodium over a 12-
week duration. Special Diet Services, Witham, 
UK, supplied the diets. This HFD was used 
specifically to study the diet effects on 
atherosclerosis as described (31). All animal care 
and procedures were closely conducted under 
ASPA 1986, UK and ethically approved by The 
University of Sheffield Ethics Committee. At the 
end of the study, the mice were euthanized and 
proximal aortae were harvested. 
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Immunohistochemistry: Sections were 
used for immunohistochemistry as previously 
described (32).  
Statistical analyses: Results are shown as 
mean ± standard error of the mean (SEM). 
Analyses were performed using Graphpad Prism 
version 6.04 (Graphpad). For multiple comparison 
tests, one way analysis of variance (ANOVA) 
followed by Tukey’s test was performed. 
Statistical significance was achieved when the p 
value was less than 0.05.  
 
RESULTS 
NE promotes IL-1 release in HCAEC: To assess 
the contribution of NE to IL-1β secretion, 
cytokine-primed ECs were treated with varying 
concentrations of NE in serum free media for 
different time points. As shown in Figure 1A, after 
2h of stimulation, NE at 1µg/ml caused significant 
(10x) release of IL-1β from cytokine-primed cells 
(198±24.85pg/ml, p<0.0001) compared to primed 
cells without NE (12.1±4.81pg/ml). This release 
significantly decreased with higher concentrations 
of NE (2µg/ml) due to a decrease in cell viability 
(50±10%). Subsequent experiments, therefore, 
used NE at 1µg/ml to give the highest amount of 
IL-1β release without a significant increase in cell 
death (Figure 1B). 
After 6h of stimulation, NE caused a 
significant increase in IL-1β secretion (Figure 1C) 
compared to cytokine stimulation alone 
(272.8±50pg/ml vs. 55.5±17.3pg/ml, p<0.001). No 
IL-1β was detected in the media of unstimulated 
cells (Figure 1C).  
To specifically confirm that the release 
was due to NE, the cells were pre-treated with the 
specific neutrophil elastase inhibitor (NEIII), 
resulting in a significant attenuation of IL-1β 
secretion. To determine the involvement of 
caspase-1, cytokine-primed ECs were pre-treated 
with YVAD-CHO and then with NE. No 
significant changes in the secreted levels of IL-1β 
were seen compared to NE alone (Figure 1C). 
Thus, NE-mediated IL-1β release in endothelial 
cells was independent of caspase-1.  
In unstimulated EC lysates, we did not 
detect any IL-1β. However, there was a significant 
IL-1β production inside cells following treatment 
with proinflammatory cytokines (Figure 1D).  The 
IL-1β levels in the lysates were not significantly 
different amongst the groups (Figure. 1D). In 
addition, NE treatment alone did not provoke IL-
1β production in the cells (Figure 1D), suggesting 
no direct effects of NE on IL-1β generation inside 
the cells. There was also no effect seen on IL-1β 
production in cell lysates by NE III or caspase-1 
inhibitors (Figure 1D).  
To confirm that NE was active over the 
duration of the study, we measured NE activity 
using quantitative cleavage of a chromogenic 
specific substrate and interestingly in the lysates 
harvested from NE-treated cells this was 
significantly increased (Figure 1E).  
Cell lysis as a mechanism of IL-1β 
secretion was ruled out by the absence of cytosolic 
enzyme lactate dehydrogenase (LDH) levels in cell 
supernatants. There were no significant changes in 
LDH levels following NE stimulation at 2 and 6h 
compared to control (Figure 1F). Since IL-1 
release could be a feature of cell apoptosis, we 
investigated caspase-3/7 activation in ECs under 
our stimulation conditions and showed no 
significant increase in NE treated cells compared 
to unstimulated ECs, cytokine stimulated cells, or 
cells in which NE effects are attenuated using 
NEIII (Figure 1G). In addition, we used propidium 
iodide (PI) in conjunction with annexin V (PI/AV) 
to determine if EC were viable, apoptotic, or 
necrotic at any timepoint used in this study. We 
did not detect any significant increase in PI/AV 
staining in NE treated cells compared to untreated 
controls (data not shown).  
In vitro, some proteases, including NE, 
have been shown to process proIL-1β into mature 
IL-1β (13). Thus, as the ELISA does not 
distinguish between pro- and mature- IL-β, we 
determined which IL-1β isoforms were present, 
and their relative respective levels, in cell lysates 
by immunoblotting. Unsurprisingly, unstimulated 
HCAEC lysates did not contain any detectable IL-
1β but full-length proIL-1β (31kDa) was seen in 
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cytokine-primed cell lysates (Figure 2Ai). 
However, after the addition of NE, there was 
cleavage of the 31kDa pro-form associated with a 
decrease in the 31kDa proIL-1β in cell lysates 
(Figure 2Ai) that was NE specific as evidenced by 
inhibition by NEIII but not YVAD. On addition of 
NE, 20kD and 17kD IL-1β forms were detected 
(Figure 2Ai). Again, this was NE specific (Figure 
2B). Interestingly, NE induced maturation of IL-
1β that was not associated with procaspase-1 
cleavage or alterations in NLRP-3 levels in lysates 
as detected by Western blot (Figure 2Aii, iii). Nor 
did we detect p20 (the product of active caspase-1) 
in cell media, indicating that cleavage and 
secretion had not occurred. NE is known for its 
proteolytic properties, therefore, to confirm that 
NE cleaved the pro-form, but not the mature form 
of IL-1, recombinant proIL-1β and recombinant 
mature IL-1β were incubated with NE in a cell-
free system. NE cleaved the pro-form of IL-1 in 
vitro (Figure 2C) but not the mature form (Figure 
2D, 2E), supporting the hypothesis that NE 
specifically cleaves the pro-form of IL-1β only. 
Taken together, these data clearly suggest that NE 
increases cytokine-induced IL-1β secretion in ECs 
via an inflammasome/caspase-1 independent 
pathway. 
NE induced secretion of extracellular vesicles 
containing bioactive IL-1 from HCAECs:  In 
immune derived cells, protected release of IL-1β 
(microvesicles, multivesicular bodies (MVB), 
exosomes) has been proposed as a mechanism for 
IL-1β trafficking to the extracellular environment 
(9,33,34). Therefore, we sought to determine 
whether there was extra-vesicular shedding 
occurring in response to NE and whether this is 
associated with IL-1β processing in HCAECs. 
  Since phosphatidylserine (PS) exposure 
has been associated with MV shedding in 
monocytes (9) and EC (24), we used annexin V 
binding (annexin V-Alexa Fluor 488) as a tool to 
visualise events in live HCAECs. Small particles 
(0.1-1µm in diameter) were observed separating 
from the cells in real time using time lapse 
imaging over duration of 6h (see video, 
supplemental material). The first MV generation 
was at 10 min, with membrane alterations at 30 
minutes after NE stimulation with large numbers 
of MVs observed at later time points (Figure 3).  
The number of MVs was quantified using flow 
cytometry and gating for annexin V (Figure 4A). 
Interestingly, there was a significant increase in 
the number of MVs isolated from ECs following 
NE treatment (two to threefold) compared to 
controls. Importantly, NE inhibition effectively 
attenuated MV formation and shedding induced by 
NE and caspase-1 inhibition had no significant 
effect (Figure 4B).  
We next investigated which IL-1β 
isoforms were inside MVs using immunoblotting. 
MVs from unstimulated cells contained no IL-1β, 
and in MVs from cytokine-primed cells (6h), 
prominent proIL-1β (31kDa) forms were detected 
(Figure 4C). In MVs isolated from the 
supernatants of NE treated cells, cleavage of the 
31kDa IL-1β isoform to approximately 20kDa-
19kDa was observed from as early as 30 minutes 
(Figure 4D) with further cleavage to the 18 and 
15kDa isoforms after 6h (Figure 4C). Treatment of 
cells with NEIII abolished any cleavage of proIL-
1β in these MVs, confirming that these bands are 
the result of direct NE activity. Cleavage of proIL-
1β continued even in the presence of YVAD with 
more prominent isoforms detected (Figure 4C). 
MVs were assessed for caspase-1 and NRLP3 
content and, interestingly, active caspase-1 p20 
and NLRP3 were not detected in MVs isolated 
from cells treated with NE or NE and YVAD 
together (data not shown), indicating that intra-
vesicle cleavage of proIL-1β is independent of 
caspase-1 activation. These findings suggest that 
either NE cleaves the released proIL-1β inside 
MVs or that NE treated cells continually generate 
more MVs containing IL-1β as a route of 
secretion.  
We next asked whether the processed IL-
1β released into cell supernatants in vesicles as a 
result of NE activation, was bioactive. We 
collected total supernatants (containing MVs) from 
NE-treated or untreated cells for 6h and applied 
them to HeLa cells expressing an IL-1RI 
responsive reporter, and measured IL-8 activity. 
We compared reporter assay output (IL-8) to 
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media obtained from unstimulated or cytokine-
primed EC +/- NE with a positive control (0.1nM 
recombinant IL-1β) or with an IL-1β neutralising 
antibody. As shown in figure 4E, supernatants 
isolated from NE activated ECs significantly 
increased IL-8 activity compared to unstimulated 
and cytokine-primed cells and this was completely 
abrogated by the neutralising antibody. In order to 
confirm that the bioactivity was due to released IL-
1β and not a result of direct NE effects on HeLa 
cells, NE (1µg/ml) was added to HeLa cells (as a 
spike) and this showed no significant IL-8 
activation. These data indicate that the IL-1β in the 
MVs is bioactive. 
MVs containing IL-1β were confirmed 
using immunogold TEM and we detected 0.2µm 
diameter MVs containing immunogold labelled 
IL-1β only in NE treated cells (Figure 4F). 
  
Mechanisms of IL-1β release in endothelial 
HCAEC: To study early MV shedding by NE, 
intracellular calcium changes were assessed. MV 
release has been linked with transient changes in 
intracellular calcium (Ca2+)i in specialised 
secretory cells (35) and IL-1β secretion in 
macrophages (33). Using a Ca2+ sensitive 
fluorometric dye, we assessed the role of (Ca2+)i in 
MV formation and release in response to NE and 
performed experiments in the presence or absence 
of exogenous Ca2+. In this experiment, (Ca2+)i is 
released from intracellular stores during an initial 
stimulation/treatment in Ca2+ free media and 
application of CaCl2 during the second phase of 
the protocol, allows Ca2+ influx inside ECs.  In 
Ca2+-free media, there was a small non-significant 
increase in cytosolic Ca2+ levels in NE treated cells 
compared to untreated cells after NE stimulation 
(Figure 5A). However, (Ca2+)i was significantly 
increased in NE stimulated cells after the addition 
of CaCl2 compared with unstimulated and 
cytokine-primed cells (Figure 5B).  This finding 
suggests that NE treatment of EC increases free 
(Ca2+)i by promoting Ca2+ influx into EC and that 
this calcium influx is associated with MV release.  
We detected small MV (approx. 200nm) 
in response to NE (assessed by flow and electron 
microscopy), characteristic of exosomes secreted 
from multivesicular bodies (MVBs) and this led us 
to study the compartmentalisation of IL-1β in EC 
(30). HCAECs +/- NE were stained using an 
immunofluorescence technique for LAMP-1 (a 
late endolysosomal marker) and IL-1β. Confocal 
images of cytokine-primed ECs stained for IL-1β 
and co-stained for LAMP-1 suggested a wide 
distribution of IL-1β throughout the cytoplasm and 
no colocalization with LAMP-1 (Figure 5C). 
Unsurprisingly, no signals were detected for IL-1β 
in unstimulated ECs (data not shown). However, 
in ECs incubated with NE for increasing times 
(30min, 1, 2h), IL-1β was co-localised with 
LAMP-1 (Figure 5D). Indeed, following a 2h 
stimulation of EC with NE, the majority of IL-1β 
was detected in MVBs (Figure 5D).    
To confirm that the site of IL-1β 
processing and secretion was indeed mediated by 
an endolysosomal mechanism, we evaluated the 
effect of bafilomycin A1 (BAF1), a lysosomal 
V/ATPase inhibitor that has been shown to prevent 
endolysysomal formation (36). Treatment of ECs 
with BAF1 (50nM) before the addition of NE 
largely decreased IL-1 levels in the supernatants 
after 6h, and that was associated with a reduction 
in pro-IL-1 cleavage in the lysates (Figure 6A, B). 
We subsequently performed TEM on cytokine-
primed HCAECs +/- NE and observed >200nm 
structures in the cytosol with classical 
morphological features of multivesicular bodies 
(MVB) (37). These were detected in close 
proximity to the plasma membrane in NE-
activated ECs but not in unstimulated ECs (Figure 
6C, panel i). Interestingly, inside the cells, the 
majority of IL-1 was detected within the MVBs 
(Figure 6C, panel ii).  
 
NE is detected in ECs and is colocalized with IL-
1β in the endothelium of mature atherosclerotic 
plaques: To follow the fate of NE in activated 
ECs, we used Alexa-Fluor 647-labelled NE and 
performed immunofluorescence staining. After 
permeabilization, we also labelled the internal 
endolysosomes with LAMP-1. Surprisingly, NE 
was detected inside cells. The enzyme co-localised 
with LAMP-1 (Figure 7A).  
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Finally, we asked whether NE could be 
detected in atherosclerotic plaques in mice to 
ascertain if NE could contribute to local IL-1β 
generation. Only in well-developed atheromatous 
lesions of ApoE-/- mice fed a high fat for 12 weeks 
was IL-1β was detected, predominantly in 
endothelial cells. Interestingly, in these lesions, 
NE also appeared to be expressed in the luminal 
endothelium (Figure 7B) and colocalized with IL-
1β-positive stained ECs (Figure 7C).  
 
DISCUSSION 
Here we describe for the first time, how coronary 
artery ECs release IL-1β, which has been a ‘holy 
grail’ of endothelial biology for many years.  We 
report that a considerable amount of IL-1β is 
released from ECs in response to NE via a 
caspase-1 independent, vesicular pathway. This is 
supported by the following lines of evidence: 1) 
Bioactive IL-1β is secreted only in MVs following 
NE treatment, 2) IL-1β secretion is unaffected by 
YVAD and occurs without caspase-1/NLRP3 
activation and 3) MVB are prevalent in primed 
NE-treated ECs and contain IL-1β protein. We 
propose that ‘protected release’(10) (i.e. contained 
within membrane-bound vesicles) of IL-1β is a 
prevalent mechanism in HCAECs. 
The endothelium is fundamental in 
atherosclerotic plaque development, not only 
during early lesion development but also later by 
controlling plaque instability (38). In 
atherosclerosis, crosstalk between circulating cells 
such as monocytes and neutrophils and the 
endothelium can cause ECs to liberate soluble 
agents perpetuating the cycle of inflammation. 
Several lines of evidence suggest that IL-1 is an 
apical cytokine in this process (39) yet its 
mechanism of release from ECs is largely 
unknown. Furthermore, the biological pattern of 
the crosstalk is not completely defined. We 
hypothesised that NE induces IL-1β secretion from 
vascular endothelium.  
Since caspase-1 has been identified as the 
main proteolytic enzyme to play a role in proIL-1β 
cleavage and secretion in monocytes and 
macrophages (40), we used a specific caspase-1 
inhibitor (YVAD-CHO) as a potential means of 
attenuating IL-1β release. Our data show that 
caspase-1 appears to be non-essential in EC in this 
setting for IL-1β cleavage and release by NE. This 
is at odds with other in vitro studies in monocytes 
(21), but in agreement with more recent data from 
other cell types (41) and in vivo models (42,43). 
Our findings are also supported by the findings of 
Guma et al. (11), who describe the presence of IL-
1β in the synovial fluid of caspase-1-/- mice. 
Moreover, our data may explain why caspase-1 
suppression did not show promise in vascular 
healing or atherosclerosis progression (32). 
It has been previously shown that IL-1 
lacks the signal peptide for directing it to the 
classical ER-Golgi secretory pathway (30). 
Therefore, IL-1β release has been proposed to 
occur by distinct mechanisms, including MV 
shedding and endolysosomal regulation (10). 
Strikingly, in HCAEC, NE induced MV shedding 
occurred independent of caspase-1 activity 
contrasting with previous investigations on 
immune cells in terms of their caspase-1 
dependency of MVs shedding. We suggest that, at 
least in HCAEC, NE is able to directly cleave the 
IL-1β precursor, which is associated with 
protected release in membrane-bound vesicles. In 
MVs, the prominent forms of IL-1β released (also 
present inside cells) were 20kDa, 18kDa and 
15kDa. These isoforms have been detected 
previously in vitro (13) and although proposed as 
5-10 fold less bioactive than the 17kDa isoform, 
they are active enough for IL-1 to bind to its 
receptors and initiate signalling. Our study is the 
first to show in intact cells that NE is capable of 
cleaving proIL-1β at multiple sites and that these 
products are bioactive.  
A common biogenesis has linked Ca2+ 
regulated MV shedding and IL-1 secretion with an 
increase in intracellular calcium levels (33). We 
are in agreement with this and demonstrated that 
NE transiently increased (Ca2+)i to a maximum 
after addition of exogenous Ca2+, suggesting that 
NE mobilized (Ca2+)i, mainly by influx of 
extracellular Ca2+. The secretory pathway 
identified here has been used to describe the 
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secretion of other non-classical proteins such as 
EGF (44).  Although a few studies have begun to 
investigate NE-mediated IL-1β secretion in renal 
disease and lung ours is the first in cardiovascular 
inflammation to propose a direct effect of NE on 
IL-1β release and to link this to a MV release 
mechanism.  
Recent immunofluorescence staining data 
in murine macrophages has shown that IL-1β does 
not colocalise with LAMP-1 in macrophages (45). 
This finding is consistent with our data in EC prior 
to NE treatment (cytokine-primed cells) where IL-
1β appears to be diffusely distributed within the 
cytoplasm. Significantly, however, 2h after NE 
treatment, colocalisation increased, strongly 
suggesting that IL-1β compartmentalisation may 
be acutely induced by NE and pre-destined for 
maturation by regulated transport. In ECs primed 
with cytokines and treated with NE, we observed 
that MVB with cytosolic IL-1β accumulated 
within cell invaginations similar to (46).  This is 
consistent with work from Rubartelli et al in 
monocytes (47). Since MVBs were not detected in 
cells that did not produce IL-1β (33), this strongly 
suggests that the MVBs are a part of the secretory 
pathway of IL-1β.  
The colocalisation of IL-1β and LAMP-1 
suggests that NE may trigger a signalling pathway 
that allows the IL-1β processing to occur in 
secretory endolysosomes (MVB). However, the 
possibility of NE internalisation within ECs, via 
endocytosis, cannot be ruled out, particularly as 
we detect enhanced NE activity in NE-treated ECs 
lysates compared with untreated and cytokine-
primed cells. In agreement with others who have 
shown that NE is internalised by macrophages (48) 
and tumour cells (27) by active transport, we also 
detected NE inside EC using confocal imaging. 
Therefore, it is possible that after internalisation of 
NE by ECs, NE enters MVBs where it cleaves 
proIL-1β.  
It is possible that NE is also causing 
release of IL-1β due to a toxicity effect, with NE 
causing cell damage and leakage of cellular 
contents. However, at the NE concentration used, 
this is unlikely to be the case as cell viability was 
not significantly affected, nor was apoptosis 
proven. Indeed, IL-1β has been shown to increase 
caspase 3/7 in cells without inducing apoptosis 
(49), which is in agreement with our data; NE 
increases IL-1β levels, which, in turn, affects 
caspase 3/7, but does not affect apoptosis. We use 
recombinant NE throughout this study, raising the 
question of what the natural source of NE would 
be and whether levels of NE would be enough to 
activate EC. Previous work by our group has 
shown IL-β is released from activated co-cultures 
of ECs and monocytes, at greater levels than from 
monocytes or ECs alone, and that an unidentified 
monocyte-derived mediator significantly 
contributed to this response (50). Taken together 
with the current findings reported here, we 
postulate that NE is the mediator released from 
monocytes and would be the natural source of NE 
in vivo. 
Given the continued prominence and 
topicality of IL-1 in the generation and progression 
of atherosclerosis (51) we studied the expression 
of NE in vivo in a recognised atherosclerosis 
preparation: aortic root plaques taken from ApoE-/- 
mice fed a high fat diet for 12 weeks. Although 
previous work has detected NE in coronary 
arteries (6) aortic aneurysms (52) and in carotid 
plaques (17), our study is the very first to 
investigate NE distribution in experimental 
atherosclerosis. Significantly, NE was mainly 
detected in the endothelium of plaques, and was 
detected alongside IL-1β. The antibody used for 
these studies recognises both proIL-1β and mature 
forms, and we show a clear cellular colocalization 
with NE in support of our data that NE activates 
and promotes secretion of IL-1β. This 
colocalization of NE and IL-1β suggests that the 
IL-1β observed is likely to be active. We propose 
that circulating NE is assimilated into developing 
plaques from degranulating immune cells during 
their passage through the main vasculature or via 
vasa vasorum where these exist. This suggestion 
remains to be clarified, and a causal connection 
between IL-1β and NE confirmed, in a future 
study utilising NE-/- mice. 
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In conclusion, we significantly add to and 
cement the emerging role of NE in IL-1 induced 
inflammation. Further, we suggest a novel 
mechanism for NE-mediated IL-1 secretion by 
ECs, namely pro-IL-1 processing in the secretory 
endolysosomes and packaging of mature bioactive 
IL-1 within MVs for release into the extracellular 
environment, as part of a single continuum 
mechanism (figure 8), which is similar to that 
previously proposed for other cell types (10). We 
detect NE and IL-1β in vivo in the setting of 
atherosclerosis within endothelium in 
atheromatous plaques. The pathophysiological 
relevance of the detection of vesicular IL-1, 
particularly derived from endothelium, gives ECs 
the potential to exert a regulatory influence upon 
atherogenesis and henceforth to become a possible 
therapeutic target by modulating IL-1 secretion in 
the local environment.  
Our findings have wider application for a 
better understanding of the role of other important 
proteases with prominent non-proteolytic and 
possibly signalling roles such as azurocidin, 
proteinase 3 and Cathepsin G and provide other 
avenues for therapeutic targets to limit the 
influence of interleukin-1.  
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FIGURE LEGENDS  
FIGURE 1: NE enhances IL-1β secretion from HCAECs by a caspase-1 independent mechanism. A) 
IL-1β is released by HCAECs after 48h stimulation with cytokines (TNF-α/IL-1α; 10ng/ml) followed by 
NE activation (0.5µg/ml - 2µg/ml) for 2h, measured by ELISA (n=3). B) Cell viability (measured by 
trypan blue) is not significantly reduced following exposure to 1µg/ml NE (n=3). C) HCAECs, incubated 
for 48h +/- cytokines then further incubated for 6h in serum free media +/- NE (1µg/ml), in the presence 
or absence of inhibitors (NEIII; 500µM & YVAD; 50µM), n=5, shows IL-1β release is increased by NE 
independent of caspase-1. D) Levels of IL-1β in cell lysates is not increased following NE incubation, 
n=5. E) Graph showing increased NE activity in EC lysates treated with NE for 6h compared to 
unstimulated cells, n=3. F) LDH levels are unchanged following NE treatment, measured in conditioned 
media or in cell lysates as a total of LDH, n=3. G) Caspase-3/7 activity is unchanged in HCAECs 
following NE treatment. HCAECs in 96 well plates (2x104 cells/well) incubated +/- cytokines (TNF-α/IL-
1α; 10ng/ml each) for 48h, were subjected to NE (1µg/ml) in serum free media for 6h (n=3). 
Campthothecin (10µg/ml) was used to induce apoptosis as a positive control.  All data are mean ± SEM, 
analysed by one-way ANOVA with Tukey’s multiple comparison multiple test, *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
FIGURE 2: NE selectively cleaves proIL-1β in primed EC lysates without caspase-1/NLRP3 
activation. A) Western blot analysis of cell lysates of primed EC +/- NE, assessed for IL-1β (i), Caspase-
1 (ii) and NLRP-3 (iii). The blots are representative of n=3, with α-tubulin levels as loading control. For 
IL-1β, recombinant IL-1β (rIL-1β; 20µg, 17kDa) was loaded as a positive control and represents the 
commonly detected mature form, whereas proIL-1β (31kDa) indicates the inactive pro-form. For Caspase-
1, activated THP-1 cell lysates were used as a positive control for the p20 isoform. B) Densitometric 
analysis of 20kDa IL-1β levels (n=3). C) Western blot illustrating the cleavage of recombinant proIL-1β 
(rProIL-1β; 20µg) by NE. rProIL-1β was incubated at 37oC (5% CO2; v/v) alone or in the presence of NE 
(1µg/ml) for 30min, 2h, and 6h. D) Western blot for recombinant mature IL-1β (rIL-1β; 20µg) in the 
presence or absence of NE, shows no cleavage (n=3) and E) ELISA for recombinant mature IL-1β shows 
no difference in levels following NE treatment. Data are mean ± SEM, analysed by one-way ANOVA and 
Tukey’s post-test, *p<0.05, **p<0.01.  
FIGURE 3: Neutrophil elastase activates microvesicle shedding from endothelial cells in a time 
dependent manner. HCAECs were left untreated or treated with cytokines (IL-1α/TNF-α) for 48h and 
then labelled with annexin-V AlexaFluor®488. After the addition of 1µg/ml of NE, cells were visualized 
in a heated chamber (5% CO2 v/v) using a confocal microscope to scan MV release. Images captured after 
10 minutes, 30 minutes, 2 hours and 6 hours show an early generation of MVs after 10min of NE 
stimulation, but more prominent at later time points. Arrowheads indicate fluorescent MVs and arrows 
represent earliest blebbing in EC treated with NE. Scale bars=50µm; the representative images are from 
three independent experiments (n=3), and have been digitally altered to remove background fluorescence. 
FIGURE 4: NE induces secretion of extracellular vesicles containing bioactive IL-1 from HCAECs 
A) Flow cytometric characterisation of MV released in response to NE. MVs were isolated and stained 
with annexin V PE-CY7 as described in the materials and methods. Analysis of MVs (red) using 
Megamex beads (blue) shows they are within the 0.2-0.9µm size limits. B) A significant increase in MV 
stained with annexin V is seen in NE treated cells compared to untreated controls. Analysis was 
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performed by Flow Jo software, n=3, mean ± SEM, 1-way ANOVA followed by Tukey’s post- test, 
*p<0.05, **p<0.01. C & D) Detection of IL-1β in isolated MVs by immunoblotting. Equal amounts of 
protein (20µg) were loaded in each lane, with rhIL-1β (20µg) used as a positive control (17kDa). Data are 
representative of n=4. E) Luciferase assay for measurement of IL-1β bioactivity in HeLa cells exposed to 
freshly harvested conditioned media (total supernatants from cytokines primed cells (TNF-α/IL-1α; 
10ng/ml each +/- NE; 1µg/ml) or rIL-1β (0.1nM) for 6h +/- anti-IL-1β β (1µg/ml). Specificity for IL-1β is 
shown by reduction of IL-8 luciferase detection following incubation with IL-1β neutralising antibody.  
Data are expressed as mean ± SEM, n=3, analyzed by one way ANOVA followed by Tukey’s test, 
****p<0.0001. F) Immunoelectron microscopic analysis of IL-1β in ECs +/- NE treatment. Anti-IL-1β 
conjugated immunogold (20-nm gold particles, arrows) was used to confirm the present of IL-1β in the 
MVs (0.2µm) released from the plasma membrane of ECs. Scale bars=0.2µm. 
FIGURE 5: Mechanisms contributing to IL-1β release in endothelial HCAEC. A & B) HCAECs 
were assayed for changes in the cytosolic-free Ca2+
 
in response to the indicated conditions. A) No 
significant change in cytosolic Ca2+ levels are seen in Ca2+ -free media. B) The fluorescent intensity of 
intracellular calcium changes after 5min of NE stimulation, in the presence of CaCl2. Data are n=6, mean 
± SEM, analysed by one-way ANOVA and Tukey’s post-test, *p<0.05, ***p<0.001. C) IL-1β co-
localises with LAMP-1 after NE stimulation. Cells were primed with cytokines (TNF- α/IL-1α; 10ng/ml 
each) followed by incubation +/- NE (1µg/ml) in serum free media over 2h, before immunostaing for IL-
1β (red) and LAMP-1 (green), scale bars; 10µm. D) Histogram showing a high correlation between IL-1β 
and LAMP-1 in ECs after NE activation.  
FIGURE 6: NE induces IL-1β release by an endolysosomal dependent mechanism. A) ELISA 
measuring IL-1β release in conditioned media of HCAECs primed with cytokines (TNF-α/IL-1α; 
10ng/ml) ± NE (1µg/ml) ± BAF1 (50nM) after 6h. Experiments are n=3, and data are mean ± SEM, 
analysed by 1-way ANOVA followed by Tukey’s post-test, *p<0.05. B) Western blot analysis of lysates 
harvested from primed HCAECs activated with NE/±BAF1 (50nM) for 6h, 20µg protein loaded per lane 
with α-tubulin used as a loading control. The blot is representative of three independent experiments. C) 
MVB characterization: i) EM analysis showing a full appearance of MVB; multivesicular bodies in NE 
treated cells in the close proximity of plasma membrane. ii) Immunolabelling with anti-IL-1β (20-nm gold 
particles; arrow) shows IL-1β within MVB (arrowhead). Scale bars=50nm 
FIGURE 7: NE is detected in ECs and is colocalized with IL-1β in the endothelium of mature 
atherosclerotic plaques. A) Confocal images showing LAMP-1 and NE in primed ECs after NE 
treatment. HCAECs were incubated +/- Alexa Fluor 647-labelled (1µg/ml) NE for 2h in serum free media 
before washing in PBS and colocalisation performed using an antibody against LAMP-1. Confocal 
images were analysed using Zeiss image and image j software, scale bars=10µm. B) 
Immunohistochemical detection of NE and IL-1β in the luminal endothelium of mouse atherosclerotic 
plaques. Paraffin embedded aortic sinuses from ApoE-/- mice fed high fat diet for 12 weeks were stained 
with primary antibodies as indicated. Specificity of staining is confirmed by no primary negative control. 
Scale bars=200µm. C) Colocalisation of IL-1-β, NE and vWF in aortic atherosclerosis. NE positivity was 
detected predominantly in the endothelium (top right panel; arrows). IL-1β positive endothelium (top left 
panel) was also detected. The bottom panels show vWF stained endothelium and DAPI for the nuclei. 
Specificity of staining is confirmed by no primary negative control. Images are representative of histology 
data obtained from a total of 6 animals. Scale bar = 100µm.  
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FIGURE 8. Schematic of the proposed mechanism of IL-1β secretion from ECs by NE. NE is 
released by circulating cells at the site of atheroma and transported by endocytosis inside the diseased 
endothelium (primed by inflammation) (i). An increase in calcium, due to NE effects, leads to 
remodelling of the cell membrane and vesiculation (ii), which in turn facilitates the shedding of MVs 
containing mature IL-1β (iii). ProIL-1β is upregulated in the inflamed endothelium (iv). NE enters MVBs 
and cleaves the proIL-1β contained within (v). MVBs also fuse to the plasma membrane and release 
exosomes containing IL-1 (vi). 
Video 1. Typical MV shedding after application of NE to ECs was observed. 
Annexin V-AlexaFluor®488 labelling to cell membranes was performed first then NE was applied to the 
cells and monitored in heated chamber (5% CO2 v/v) using an Inverted widefield fluorescence 
microscope Leica AF6000 Time Lapse, as indicated in the materials and methods, for 2h. MVs clearly 
bud off from ECs starting at 10-15 minutes of NE stimulation and continued for 2h. 2min intervals are 
shown, 200x magnification was used. 
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Figure 3: 
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Figure 4: 
 
Neutrophil elastase promotes endothelial IL-1 secretion. 
	  
 
	  
13	  
Figure 5. 
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Figure 6. 
 
 
 
 
 
 
 
 
 
 
 
Neutrophil elastase promotes endothelial IL-1 secretion. 
	  
 
	  
15	  
Figure 7. 
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Figure 8 
 
 
 
 
 
